These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 18703606)
21. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy. Fonge H; Lee H; Reilly RM; Allen C Mol Pharm; 2010 Feb; 7(1):177-86. PubMed ID: 19924993 [TBL] [Abstract][Full Text] [Related]
22. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342 [TBL] [Abstract][Full Text] [Related]
23. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534 [TBL] [Abstract][Full Text] [Related]
24. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070 [TBL] [Abstract][Full Text] [Related]
25. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population. Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968 [TBL] [Abstract][Full Text] [Related]
26. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates. Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100 [TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253 [TBL] [Abstract][Full Text] [Related]
28. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. Cai Z; Chen Z; Bailey KE; Scollard DA; Reilly RM; Vallis KA J Nucl Med; 2008 Aug; 49(8):1353-61. PubMed ID: 18632822 [TBL] [Abstract][Full Text] [Related]
29. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
30. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729 [TBL] [Abstract][Full Text] [Related]
32. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers. Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198 [TBL] [Abstract][Full Text] [Related]
33. 111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors. Chan C; Cai Z; Su R; Reilly RM Nucl Med Biol; 2010 Feb; 37(2):105-15. PubMed ID: 20152709 [TBL] [Abstract][Full Text] [Related]
34. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. Luo TY; Cheng PC; Chiang PF; Chuang TW; Yeh CH; Lin WJ Ann Nucl Med; 2015 Jan; 29(1):52-62. PubMed ID: 25238789 [TBL] [Abstract][Full Text] [Related]
35. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935 [TBL] [Abstract][Full Text] [Related]
36. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541 [TBL] [Abstract][Full Text] [Related]
37. In vitro cytotoxicity of Auger electron-emitting [ Othman MFB; Verger E; Costa I; Tanapirakgul M; Cooper MS; Imberti C; Lewington VJ; Blower PJ; Terry SYA Nucl Med Biol; 2020; 80-81():57-64. PubMed ID: 31889612 [TBL] [Abstract][Full Text] [Related]
38. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In. Liu X; Wang Y; Nakamura K; Kawauchi S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ J Nucl Med; 2009 Apr; 50(4):582-90. PubMed ID: 19289423 [TBL] [Abstract][Full Text] [Related]
39. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway. Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825 [TBL] [Abstract][Full Text] [Related]
40. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu. Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]